Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics


Poseida Therapeutics Inc. (PSTX): $9.47

0.13 (+1.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PSTX Stock Price Chart Interactive Chart >

Price chart for PSTX

PSTX Price/Volume Stats

Current price $9.47 52-week high $17.62
Prev. close $9.34 52-week low $7.63
Day low $9.17 Volume 273,000
Day high $9.64 Avg. volume 313,936
50-day MA $8.84 Dividend yield N/A
200-day MA $9.75 Market Cap 588.61M

Poseida Therapeutics Inc. (PSTX) Company Bio


Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.


PSTX Latest News Stream


Event/Time News Detail
Loading, please wait...

PSTX Latest Social Stream


Loading social stream, please wait...

View Full PSTX Social Stream

Latest PSTX News From Around the Web

Below are the latest news stories about Poseida Therapeutics Inc that investors may wish to consider to help them evaluate PSTX as an investment opportunity.

Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held virtually via live webcast on Wednesday, June 16, 2021 at 1:00pm PT. Stockholders of record at the close of business on April 20, 2021, are entitled to vote in the Annual Meeting.

Yahoo | June 2, 2021

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021.

Yahoo | May 11, 2021

Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today will give multiple oral and poster presentations at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting being held May 11-14, 2021.

Yahoo | May 11, 2021

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:

Yahoo | April 8, 2021

Why Poseida Therapeutics Stock Is Popping Today

What happened Shares of Poseida Therapeutics (NASDAQ:PSTX) were jumping 21.2% higher as of 12:08 p.m. EST on Wednesday. The big gain came with the company providing a pipeline update at its virtual R&D Day today.

Yahoo | February 24, 2021

Read More 'PSTX' Stories Here

PSTX Price Returns

1-mo 12.74%
3-mo -8.77%
6-mo -9.81%
1-year N/A
3-year N/A
5-year N/A
YTD -13.67%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6677 seconds.